Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers in this study are comparing two different treatments for Hodgkin lymphoma (HL). The people in this study have early-stage (stage 1 or 2) HL that has not yet been treated.
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers want to find the best dose of JNJ-79635322 to use in people with multiple myeloma or AL amyloidosis. The people in this study have multiple myeloma or AL amyloidosis that keeps growing even after treatment. Multiple myeloma is a cancer of the bone marrow. AL amyloidosis happens when a protein called amyloid builds up in organs and prevents them from working properly.
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
CAR T-cell therapies are a form of immunotherapy where some of a patient's T cells are removed, modified in the laboratory to recognize a protein on cancer cells, multiplied, and returned to the patient to provoke an immune attack against cancer. Sometimes the new T cells cause side effects related to the immune system's response to the treatment.
Researchers want to find the best dose of BMS-986453 to treat multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even after treatment.
After people receive chemotherapy for colon cancer, doctors may be able to detect tumor DNA in the blood ("circulating tumor DNA" or ctDNA). If there is ctDNA in the blood, a patient's cancer may be more likely to come back. It is standard for people with ctDNA in their blood to be monitored ("active surveillance"), but investigators would like to know if immediate treatment of these patients can prevent cancer recurrence.
Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.
